2007 |
Dr. Frank Jeblonski |
New developments in European registration procedures and requirements, in particular consideration of biological/biotechnological-derived medicinal products |
|
|
2007 |
Dr. Anita Jörg |
Medicinal products during pregnancy and lactation an issue of risk management *** |
|
|
2007 |
Anja Karstens |
Differences between EU and US registration requirements for sterile human and veterinary products (quality part) for: a) First filing b) CMC changes |
|
|
2007 |
Dr. Bianca Krafft |
Scientific Advice - Value Adding Strategies for Regulatory Agencies and Pharmaceutical Companies *** |
|
|
2007 |
Michaela Krause |
ICH Q8 Pharmaceutical Development, ICH Q9 Quality Risk Management, ICH Q10 Pharmaceutical Quality System: vision, concept and their potential impact on industry and regulators will they foster innovation? *** |
|
|
2007 |
Dr. Katrin Neubert |
Development of a rationale for deriving acceptance criteria for the validation of analytical methods in the pharmaceutical quality control |
|
|
2007 |
Michaela Oppold |
The opportunities of the new Regulation on medicinal products for paediatric use for existing marketing authorisations on the example of an off-patent drug substance |
|
|
2007 |
Ariane Prochaska |
Assignment of GMP data - within application dossiers and during external inspections |
|
|
2007 |
Dr. Ursula Protin |
First experiences with Conditional Marketing Authorisations in the EU: requirements, obligations, initial experiences and perspectives *** |
|
|
2007 |
Susanne Rathmann |
Site Master File, a competent regulatory document *** |
|
|
2007 |
Dr. Herta Reile |
Implications of the new CHMP Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products Summary *** |
|
|
2007 |
Dr. Tatjana Reinholz |
Life cycle management of a marketed medicinal product in view of GMP and regulatory requirements and impact of Product Quality Reviews *** |
|
|
2007 |
Dr. Silvia Sanner |
Registration Procedures in South Africa |
|
|
2007 |
Dr. Dirk Schmidt |
Impact and Consequences of the PAT Initiatives by FDA and EMEA on New Chemical Entity Synthesis *** |
|
|
2007 |
Karin Schöpf |
Global Pharmaceutical Markets and the Influence of the International Organizations WHO and ICH *** |
|
|
2007 |
Dr. Susanne Sommer |
Package Leaflets: Testing and harmonisation in relation to the overall business process in regulatory procedures - An example of the impact of changing regulatory requirements *** |
|
|
2007 |
Dr. Dagmar Theis |
Legal Framework for Compassionate Use in the European Union - Comparison of the Implementation of Compassionate Use Programmes by Means of Selected European Member States |
|
|
2007 |
Sabine Wägele |
The Global Marketing Authorisation according to Article 6 of Directive 2001/83/EC, as amended *** |
|
|
2007 |
Dr. Nicole Wagner |
International Nonproprietary Names (INNs) - A Critical Issue For Biological Medicinal Products *** |
|
|
2007 |
Dr. Michael Walser |
Analytical Method Validation: Compilation of Relevant Legislation, Guidelines, and Literature |
|
|